New book by Larry Connors Click here Improve your trading - See how
As a result of these findings, less expensive, more reliable cells from a rat coupled with a 384-well assay format can result in reliable classification and risk-ranking of compounds for purposes of hit-to-lead prioritization and chemical class selection. In addition, the Cellumen in vitro rodent safety assessment panel provides robust dose- and time-dependent mechanistic profiles for each compound, allowing for de-risking compounds for specific mechanisms of toxicity.
The internal study, completed by Cellumen, focused on a set of 178 compounds spanning diverse chemical classes with published human DILI scores. Cellumen applied its proprietary Rat Hepatocyte Early Safety Assessment Panel consisting of freshly harvested hepatocytes, eight cellular features, three time points, and a 10 point dose response. The panel was analyzed on a high-content imaging platform and a classifier constructed to predict human DILI scores. Using this optimized Rodent Hepatocyte Panel, Cellumen achieved 100 percent specificity with nearly 50 percent sensitivity.
"We were excited by these findings, since we did not expect the concordance of human-to-human and rat-to-human DILI predictivity to be so strong," says Don Taylor, Vice President of Corporate Development for Cellumen. "However, since Cellumen measured molecular mechanisms common to both species, these results may not be as surprising as initially thought."
The results indicate that its in vitro Rat Hepatocyte Early Safety Assessment Panel can offer Cellumen customers higher throughput and lower cost solutions for human DILI predictivity than other options currently available.
About Cellumen
Cellumen is the leading early safety assessment innovator providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen's Cellular Systems Biology solutions are driving early safety assessment by addressing the full complexity of disease and safety. Leading global organizations, including top pharmaceutical companies, the EPA, FDA, and NIH, partner with Cellumen. Cellumen is a partner company of Safeguard Scientifics. Other investors include Novitas Capital, the Pittsburgh Life Sciences Greenhouse and Innovation Works. For more information about Cellumen, please visit www.cellumen.com.
SOURCE: Cellumen, Inc.
For Cellumen Gregory FCA Theresa Murray, 610-642-8253 x164 Theresa@GregoryFCA.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
